Immunotherapy Plus Chemotherapy Before Lung Cancer Surgery Significantly Improves Long-term Survival
Adding immunotherapy (nivolumab) to chemotherapy before surgery significantly improved long-term overall survival for patients with operable non-small cell lung cancer (NSCLC) compared to chemotherapy alone.